If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

PSA Screening Reduces Prostate Cancer Mortality, European Study Shows

May 24, 2012

The European Randomized Study of Screening for Prostate Cancer (ERSPC), which included 186,160 men, suggests that PSA screening can lower prostate cancer mortality rates.
 

New Assay Identifies Men Who May Be at Lower Risk for PCa Recurrence After Surgery

May 23, 2012

A recently approved diagnostic assay may improve clinicians' ability to predict a prostate cancer patient's risk of clinical recurrence after radical prostatectomy (RP), a company announced at the American Urological Association 2012 annual meeting.
 

Oral Drug Prolongs Survival in Men with Late-Stage PCa

May 23, 2012

Enzalutamide, an investigational oral medication formerly known as MDV3100, prolongs survival by nearly five months in men with late-stage prostate cancer previously treated with docetaxel, according to data presented at the American Urological Association 2012 annual meeting.
 

Intermittent ADT May Offer Survival Edge in Advanced Prostate Cancer

May 22, 2012

Intermittent androgen deprivation (IAD) therapy is associated with improved all-cause and prostate cancer (PCa)-specific mortality among elderly patients with advanced PCa, according to data presented at the American Urological Association 2012 annual meeting.
 

Durable Oncologic Outcomes Reported for RARP

May 22, 2012

Robotic-assisted radical prostatectomy (RARP) is associated with long-term biochemical relapse-free survival, according to a study presented at the American Urological Association 2012 annual meeting.
 

Urologists Condemn Task Force's Anti-PSA Testing Stance

May 22, 2012

The U.S. Preventive Services Task Force (USPSTF) on May 21 released its final recommendations on PSA-based screening for prostate cancer (PCa), which advises against the practice and gives it a grade D rating, meaning the task force believes there is "moderate or high certainty that the service has no net benefit or that the harms outweigh the benefit."
 

UTUC Tumor Location Affects Oncologic Outcomes

May 21, 2012

Tumor location independently predicts cancer-specific survival (CSS) and recurrence-free survival (RFS) in patients with upper tract urothelial carcinoma (UTUC), researchers reported at the American Urological Association 2012 annual meeting.
 

Post-RP Survival Unaffected by Early Biochemical Recurrence

May 21, 2012

Early biochemical recurrence after radical prostatectomy (RP) has no effect on survival among patients with low-risk prostate cancer (PCa), according to a study presented at the American Urological Association 2012 annual meeting.
 

HIFU Salvage Following EBRT Offers Good PCa Control

May 21, 2012

High-intensity focused ultrasound (HIFU) provides shows promise as a salvage treatment option men with recurrent prostate cancer (PCa) following external beam radiotherapy (EBRT), data presented at the American Urological Association annual meeting suggest.
 

PCa-Specific Survival Can Be Good Even with Positive Nodes

May 21, 2012

Prostate cancer (PCa) patients with lymph node positive disease found at radical prostatectomy (RP) can experience durable cancer-specific and metastases-free survival, researchers reported at the American Urological Association 2012 annual meeting.
 

Cure Possible Despite Positive Lymph Nodes

May 21, 2012

Long-term PSA relapse-free survival after radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is possible in a subset of patients with low volume nodal metastases, a researcher reported at the American Urological Association 2012 annual meeting.
 

Inappropriate Post-RP Medication Use Found

May 20, 2012

A significant proportion of men take 5-alpha reductase inhibitors (5-ARIs) and alpha blockers following radical prostatectomy (RP) even though these medications have no proven role post-RP, according to study findings presented at the American Urological Association 2012 annual meeting.
 

Bladder Cancer More Likely with Radiotherapy

May 20, 2012

Radiation therapy for prostate cancer (PCa) is associated with a greater likelihood of bladder cancer development compared with radical prostatectomy (RP), Japanese researchers reported at the American Urological Association 2012 annual meeting.
 

Findings Support Use of Salvage RALP

May 20, 2012

Salvage robotic-assisted laparoscopic prostatectomy (RALP) for recurrent prostate cancer (PCa) appears to be safe and offers outcomes favorable to those of open salvage radical prostatectomy, investigators reported at the American Urological Association 2012 annual meeting.
 

Smokers Have Worse PCa Outcomes After EBRT

May 20, 2012

Cigarette smoking is associated with an increased risk of prostate cancer (PCa) progression and genitourinary (GU) toxicities following treatment with external beam radiation therapy (EBRT), researchers reported at the American Urological Association 2012 annual meeting.
 

PCa Patient Survival Better with RP

May 20, 2012

Radical prostatectomy (RP) is associated with better overall and disease-specific survival compared with external beam radiation therapy (EBRT) for localized prostate cancer (PCa), according to findings presented at the American Urological Association 2012 annual meeting.
 

Marriage Has a Positive Effect on Prostate Cancer Outcomes

May 20, 2012

Being married is a plus when it comes to prostate cancer (PCa) outcomes, according to the findings of two studies presented at the American Urological Association 2012 annual meeting.
 

Circumcision May Lower Prostate Cancer Risk

May 17, 2012

Circumcision may help protect against prostate cancer, according to researchers in Seattle.
 

Optimal Sequencing of the New Prostate Cancer Drugs: An Interview with E. David Crawford, MD

May 15, 2012

Several new drugs have become available for treating advanced prostate cancer in the past year and a half. E. David Crawford, MD, head of urologic oncology at University of Colorado (UC) Hospital and an investigator at the UC Cancer Center, both in Aurora, and UC colleague Thomas W. Flaig, MD, recently published a review of these agents. Dr. Crawford talks to Renal & Urology News about the possible ways in which these drugs might be used.
 

Prostate Cancer Outcome Not Tied to Complementary Medicine

May 07, 2012

Although widely used, complementary and alternative medicine (CAM) does not impact patient satisfaction with treatment or patient-reported outcomes after treatment for localized prostate cancer.
 

Vitamin D May Help Prostate Cancer Patients

May 05, 2012

Small study shows benefit, but some experts urge caution.
 

Selected Prostate Cancer Patients May Benefit from HIFU

May 04, 2012

High intensity focused ultrasound (HIFU) may provide an alternative to traditional treatment for localized prostate cancer. British researchers report this use of ultrasound may be high beneficial in a select group of prostate cancer patients.
 

Prostate Imaging System Receives FDA Approval

May 02, 2012

The device may improve clinicians' ability to diagnose prostate cancer.
 

Prostate Cancer Screening: Moving Beyond PSA

May 01, 2012

More than 1 million prostate biopsies are performed annually in the United States, predominantly driven by elevations in PSA.
 

After Radical Prostatectomy, Patient Learns He Never Had Prostate Cancer

May 01, 2012

Dr. B, 57, was a urologist with a busy private practice. One of his patients was Mr. O, 69, who had an abnormal PSA result.
 

Radiotherapy Added to ADT Beneficial

May 01, 2012

Adding radiotherapy to androgen deprivation therapy (ADT) improves outcomes in patients with locally advanced prostate cancer (PCa) and can be considered a standard treatment option.
 

Circumcision May Reduce PCa Risk

April 28, 2012

Recent population-based study findings indicate that circumcision before first sexual intercourse is associated with a reduction in the relative risk of prostate cancer (PCa).
 

New Urine-Based Assay Helps Determine Need for Repeat Biopsy

April 25, 2012

A newly approved prostate cancer gene 3 assay may help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
 

Peripheral Androgen Blockade Feasible for PSA Relapse

April 24, 2012

Peripheral androgen blockade with a combination of finasteride and flutamide is feasible for prostate cancer patients who experience biochemical failure after definitive local therapy, researchers reported online ahead of print in Cancer.
 

Radical Surgery Hard to Justify for Low-Risk Prostate Cancer

April 23, 2012

Radical prostatectomy (RP) for prostate cancer (PCa) is difficult to justify for patients with Gleason 6, T1 disease, researchers concluded.
 

New Oral Drug May Aid Survival in CRPC Patients

April 19, 2012

An investigational oral agent known as MDV-3100, which halts androgen signaling, may significantly improve survival in men with metastatic castration-resistant prostate cancer (CRPC).
 

HIFU Focal Therapy May Be a Viable Option for Prostate Cancer

April 18, 2012

Focal therapy for localized prostate cancer is associated with a low rate of erectile problems and urinary incontinence a year after treatment, according to a small prospective study.
 

Perineural Invasion Predicts PSA Relapse After Brachytherapy

April 16, 2012

Perineural invasion (PNI) and post-treatment PSA levels at 12 months strongly predict long-term PSA relapse-free survival (PRFS) after definitive brachytherapy seed implantation for prostate cancer (PCa), according to a study.
 

BMD Loss Occurs Early in Androgen Deprivation Therapy

April 12, 2012

Study finds loss evident in men treated with ADT for nonmetastatic, hormone-sensitive prostate cancer
 

BPH Drugs Found to Decrease PSA Doubling Times

April 12, 2012

Men with prostate cancer on active surveillance (watchful waiting) may benefit from treatment with finasteride or dutasteride.
 

Irbesartan May Preserve Erectile Function After RRP

April 10, 2012

Regular irbesartan use after nerve-sparing radical retropubic prostatectomy (RRP) could improve postoperative recovery of erectile function among patients with normal preoperative erectile function, according to researchers.
 

Should percent free PSA be used in the decision to perform initial prostate biopsy in men with moderately elevated PSA?

April 06, 2012

A recently published paper reported on the development of an improved nomogram for predicting outcomes of initial biopsies based on readily available clinical information.
 

Brachytherapy May Be Underused

April 06, 2012

Brachytherapy appears to have significant advantages over EBRT in the treatment of men with low-risk and intermediate-risk prostate cancer.
 

Prostate Tumor Hypoxia Predicts PCa Recurrence

April 05, 2012

Men with intermediate-risk prostate cancer (PCa) who have low oxygen levels in their prostate tumors prior to radiation treatment are at increased risk of PCa recurrence, according to researchers.
 

Prostate Cancer in Blacks Linked to Central Adiposity

April 02, 2012

Greater central adiposity increases the risk of prostate cancer (PCa) in black men, according to a population-based study.
 

Proton Therapy Not Better than IMRT

April 02, 2012

New data suggest that proton therapy may be associated with a higher rate of gastrointestinal problems and may not produce better outcomes than IMRT in men with localized prostate cancer.
 

PCa Risk Higher In Men with Heart Disease

April 01, 2012

Coronary artery disease (CAD) was associated with a 35% increased risk of a prostate cancer (PCa) diagnosis.
 

Prostate Cancer Prospective Cohort

April 01, 2012

A look at the following clinical trial: Prostate Cancer Prospective Cohort.
 

Should bone scans be ordered for almost every patient newly diagnosed with prostate cancer?

March 30, 2012

Most men with incidental prostate cancer do not require staging imaging, according to guidelines.
 

Targeted Fusion Biopsy May Improve PCa Detection

March 30, 2012

SAN FRANCISCO—Prostate cancer (PCa) detection rates may be markedly improved by adding targeted fusion biopsy to conventional blind random biopsies, according to a new study presented at the 37th Annual Scientific Meeting of the Society of Interventional Radiology.
 

Biomarkers May Aid Active Surveillance Management for Prostate Cancer

March 27, 2012

Two urine-based biomarkers are associated with prostate cancers that are likely to be aggressive and potentially life-threatening among men who are on an active surveillance for their disease.
 

Encouraging Findings for PCa Focal Cryotherapy

March 23, 2012

Primary focal cryotherapy for low-intermediate risk unilateral prostate cancer (PCa) offers encouraging oncologic and functional outcomes after a median follow-up of 3.7 years, researchers reported.
 

In light of recent findings, would you consider prescribing dutasteride to men with low-risk prostate cancer to reduce their risk of PCa progression?

March 23, 2012

A randomized, double-blind study showed that men who took dutasteride for three years had a significant decreased risk of PCa progression compared with men who took placebo
 

ADT for Prostate Cancer Does Not Boost Cardiovascular Mortality

March 20, 2012

Use of short-course androgen deprivation therapy (ADT) may improve overall and disease-specific survival but does not appear to increase cardiovascular mortality in men with clinically-localized prostate cancer.
 

PSA Screening Lowers Prostate Cancer Mortality

March 16, 2012

PSA-based screening significantly decreases the risk of dying from prostate cancer (PCa), according to updated results of a large European study.
 

Have you ever prescribed sipuleucel-T for a prostate cancer patient?

March 16, 2012

Nearly two years have passed since the FDA approved sipuleucel-T—a therapeutic cancer vaccine developed and marketed by Dendreon Corp. as Provenge.
 

The Case for Brachytherapy: An Interview with Michael F. Sarosdy, MD

March 14, 2012

Having performed more than 1,200 brachytherapy treatments since 1996 and conducting research in this field, urologic oncologist Michael F. Sarosdy, MD, founder of South Texas Urology & Urologic Oncology, in San Antonio, is convinced that this is a far better choice than surgery for most men with prostate cancer, regardless of the patient's age or tumor characteristics.
 

Statins May Lower Prostate Cancer Death Risk

March 13, 2012

Men who take statins may have a lower risk of dying from prostate cancer (PCa), new findings suggest.
 

Eating Rye Bread in Adolescence May Prevent Aggressive Prostate Cancer

March 13, 2012

Consuming rye bread in adolescence may be protective against the development of aggressive prostate cancer later in life.
 

Prostate Cancer Risk Higher in Diabetics

March 09, 2012

Men with diabetes mellitus (DM) are more likely than those without the disease to have prostate cancer (PCa) found in prostate biopsy specimens, a study found.
 

Prostate Cancer Severity May Depend on Prostate Size

March 07, 2012

The size of man's prostate may help predict the severity of his prostate cancer.
 

A Better Way to Screen for Prostate Cancer

March 01, 2012

Novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinical significant prostate cancer.
 

Adverse RP Effects Not Lessened with Robotics

March 01, 2012

Patients undergoing prostate cancer surgery will face similar risks for incontinence and sexual problems whether they undergo robotic-assisted laparoscopic radical prostectomy (RP) or open RP.
 

Highlights of the GU Cancers Symposium

March 01, 2012

The March issue features coverage of the 2012 Genitourinary (GU) Cancers Symposium, which was held in San Francisco.
 

PSMs Predict PCa Recurrence in Some Men

February 29, 2012

Positive surgical margins (PSMs) are a risk factor for biochemical recurrence of prostate cancer (PCa) in patients who have undergone radical prostatectomy for intermediate-risk disease.
 

Immediate Salvage Radiotherapy Urged for Recurrent PCa

February 27, 2012

PARIS—Salvage radiotherapy (SRT) for recurrent prostate cancer (PCa) should be given at the earliest sign of biochemical failure, researchers reported at the 27th Annual Congress of the European Association of Urology.
 

Data Support Cystoscopy Prior to Brachytherapy

February 27, 2012

PARIS—Cystoscopy prior to low dose rate (LDR) brachytherapy for prostate cancer is feasible and useful in identifying patients who require further investigation or intervention before seed implantation, researchers reported at the 27th Annual Congress of the European Association of Urology.
 

High-Grade Prostate Cancer Linked to Metabolic Syndrome

February 27, 2012

PARIS—Metabolic syndrome does not increase men's risk of prostate cancer (PCa) overall, but it does increase their risk of aggressive PCa, researchers reported at the 27th Annual Congress of the European Association of Urology.
 

NSAID Use May Increase Prostate Cancer Risk

February 25, 2012

PARIS—Contrary to the findings of previous epidemiologic studies, a new study found that use of nonsteroidal anti-inflammatory agents (NSAIDs) is associated with an increased risk of prostate cancer (PCa) overall and aggressive PCa, Finnish researchers reported at the 27th Annual Congress of the European Association of Urology.
 

Post-Prostate Biopsy Infections a Significant Global Problem

February 25, 2012

PARIS—Infectious complications following a transrectal prostate biopsy have become a significant health problem globally, data presented at the 27th Annual Congress of the European Association of Urology suggest.
 

A New Radiotherapy Option for Prostate Cancer

February 21, 2012

Noninvasive brachytherapy-like treatment may be a new option for men with prostate cancer.
 

Dietary Calcium May Decrease Prostate Cancer Risk

February 17, 2012

Dietary calcium is associated with lower risk for prostate cancer (PCa), particularly among black men, and with a lower risk for high-grade prostate cancer among all men, according to a study involving 108 U.S. veterans with biopsy-positive prostate cancer, 161 biopsy-negative controls, and 237 healthy controls.
 

PCA3 Test Okayed to Help Decide Need for Repeat Prostate Biopsy

February 15, 2012

The FDA has approved the first urine-based molecular test to help determine if men who have had a prior negative prostate biopsy should undergo a repeat biopsy.
 

Researchers Find Mutation that May Hike Prostate Cancer Risk

February 14, 2012

Researchers at Johns Hopkins University in Baltimore have found a specific gene mutation that may put men at a 10-20 times greater risk of developing prostate cancer.
 

Are you more likely today to recommend active surveillance for selected patients with low-risk prostate cancer than you were five years ago?

February 13, 2012

Evidence is accumulating that active surveillance is an appropriate way to manage low-risk prostate cancer in selected men, with curative treatment delayed until it is warranted by indicators of disease progression.
 

Proton Therapy Safe, Effective for Prostate Cancer

February 08, 2012

Two new studies suggest that proton therapy is a safe and effective treatment for prostate cancer.
 

Never-Married Men Fare Worse After Prostate Cancer Surgery

February 04, 2012

SAN FRANCISCO—Prostate cancer patients who have never been married are more likely than married men to die from their disease following radical prostatectomy (RP), according to study findings presented here at the annual Genitourinary Cancers Symposium.
 

Very Low Testosterone Hikes Prostate Cancer Recurrence Risk

February 04, 2012

SAN FRANCISCO—Extremely low levels of testosterone in men after they have undergone radical prostatectomy (RP) for intermediate- to high-risk prostate cancer are associated with an elevated risk for biochemical recurrence of the disease, researchers reported here at the annual Genitourinary Cancers Symposium.
 

Brachytherapy May Be An Option for Men with High-Risk Prostate Cancer

February 04, 2012

SAN FRANCISCO—Brachytherapy may be a treatment option for patients with high-risk prostate cancer (HRPC), according to data presented here at the annual Genitourinary Cancers Symposium.
 

Prostate Cancer Linked to Heavy Alcohol Intake

February 03, 2012

SAN FRANCISCO—Heavy ethanol intake is associated with an increased risk of prostate cancer (PCa) among low-risk men with at least one prior negative prostate biopsy, investigators reported here at the annual Genitourinary Cancers Symposium. It also is associated with an elevated risk for high-grade PCa.
 

PSA Testing Rates Unchanged for Elderly Men Despite Task Force Guidelines

February 03, 2012

SAN FRANCISCO—PSA testing rates for men aged 75 years and older did not decline despite a 2008 U.S. Preventive Services Task Force (USPSTF) recommendation against PSA screening for men in this age group, according to study findings presented at the annual Genitourinary Cancers Symposium.
 

Prostate Cancer Patients Far More Likely to Die from Other Causes

February 03, 2012

SAN FRANCISCO—Elderly men who receive definitive local treatment for prostate cancer (PCa) are much more likely to die from causes other than their cancer, a finding that could inform doctor-patient discussions about treatment for localized PCa, investigators reported here at the annual Genitourinary Cancers Symposium.
 

Many Metastatic Prostate Cancers Go Untreated

February 03, 2012

SAN FRANCISCO—Many patients with metastatic prostate cancer (PCa) never receive anticancer treatment, and older age, lower income, and lack of private health insurance may be among the reasons, according to data presented here at the annual Genitourinary Cancers Symposium.
 

Novel Drug Prolongs Survival in Men with Advanced Prostate Cancer

February 03, 2012

SAN FRANCISCO—A novel medication may provide a new standard of care for the treatment of patients with castration-resistant prostate cancer (CRPC) and bone metastases, researchers reported here at the annual Genitourinary Cancers Symposium.
 

Obesity Raises Prostate Cancer Risk in All Races, Ethnicities

February 03, 2012

A new study suggests that obesity is associated with higher rates of prostate cancer screening across all races/ethnicities.
 

Herbal Product May Be Useful for Recurrent Prostate Cancer

February 02, 2012

SAN FRANCISCO—A combination herbal supplement may benefit men with recurrent prostate cancer (PCa), according to a findings presented here at the annual Genitourinary Cancers Symposium.
 

First PSA Results Predict Long-Term Prostate Cancer Risk

February 02, 2012

SAN FRANCISCO—PSA levels at the first date of testing may predict a man's long-term risk of prostate cancer and mortality in the general population, Danish investigators reported here at the annual Genitourinary Cancers Symposium.
 

Eating Rye Bread in Adolescence May Cut Prostate Cancer Risk

February 02, 2012

SAN FRANCISCO—Greater rye bread consumption in adolescence may be associated with a decreased risk of prostate cancer, especially advanced disease, according to findings presented here at the annual Genitourinary Cancers Symposium.
 

Empiric Antibiotics for Elevated PSA of No Clinical Benefit

February 02, 2012

SAN FRANCISCO—New findings presented here at the annual Genitourinary Cancers Symposium challenge the widespread practice of placing patients on an empiric course of antibiotics for a newly elevated PSA level.
 

Proton Therapy No Better than IMRT for Prostate Cancer

February 02, 2012

SAN FRANCISCO—Proton therapy is no better than intensity modulated radiotherapy (IMRT) as a treatment for localized prostate cancer, and it is associated with greater gastrointestinal toxicities, researchers reported here at the Genitourinary Cancers Symposium.
 

Imaging May Spare Nerves in Prostate Cancer Surgery

January 25, 2012

Preoperative MRI led to a change in surgical plan in 27% of robot-assisted prostatectomies
 

Dutasteride Delays Progression of Low-Risk Prostate Cancer

January 25, 2012

For men with low-risk prostate cancer who undergo active surveillance, treatment with dutasteride delays the time to cancer progression, a study found.
 

Prostate Biopsies Rarely Lead to Hospitalization

January 12, 2012

Hospital admissions related to a prostate needle biopsy (PNB) are on the increase, but they occur in less than 1% of men who undergo PNB and are not associated with excess mortality, researchers concluded in an online report in European Urology.
 

Gene Variant Linked to Hereditary Prostate Cancer

January 11, 2012

Mutation more common in early-onset, familial cancers
 

Minimally Invasive Surgery for Prostate Cancer Increasing, Offers Better Results

December 28, 2011

Use of minimally invasive radical prostatectomy (MIRP) for patients with prostate cancer (PCa) increased and the use of retropubic radical prostatectomy (RRP) decreased significantly from 2003 to 2007, a study found.
 

Small Prostate Increases Risk of PCa Upgrade

December 20, 2011

Smaller prostates in men with low risk prostate cancer (PCa) may indicate a greater likelihood of harboring tumors of higher grade than indicated by prostate biopsy, according to investigators.
 

PSA Threshold for Biopsy Remains Stable

December 20, 2011

A widely used PSA threshold for recommending prostate biopsy (4.0 ng/mL) has remained unchanged over time despite some calls to lower the threshold, according to researchers.
 

Most Deaths After Radical Prostatectomy Not Due to Prostate Cancer

December 14, 2011

Men who undergo radical prostatectomy (RP) for prostate cancer (PCa) are much more likely to die from cardiovascular disease (CVD) and other cancers than from PCa, according to researchers.
 

NIH Panel Endorse Active Monitoring for Men with Low-Risk Prostate Cancer

December 13, 2011

An independent panel convened by the National Institutes of Health (NIH) has recommended close monitoring rather than immediate treatment for men with localized, low-risk prostate cancer (PCa). Treatment can be delayed until warranted by disease progression.
 

Triple-Regimen Benefits Men with Intermediate-Risk Prostate Cancer

December 12, 2011

Combined external beam radiation therapy (EBRT) with a brachytherapy boost plus androgen deprivation therapy (ADT) is associated with excellent disease-free survival among men with intermediate-risk prostate cancer (PCa), researchers reported.
 

Well-Done Ground Beef May Raise Risk of Aggressive PCa

December 05, 2011

A study of 470 cases of aggressive prostate cancer (PCa) and 512 controls demonstrated that higher consumption of any ground beef or processed meats was associated with an increased risk of aggressive PCa, particularly when the meat was grilled or barbecued and when well-done.
 

ADT Use Declining, Patterns of Use Changing

November 26, 2011

Initiation of androgen deprivation therapy (ADT) for prostate cancer (PCa) is declining and patterns of use are changing, according to recently published data from a Canadian study.
 

Obesity Raises Metastasis Risk in Prostate Cancer Patients on ADT

November 25, 2011

Obesity is associated with an increased risk for prostate cancer (PCa) progression among PCa patients treated with androgen deprivation therapy (ADT) after radical prostatectomy, according to a study.
 

Bone-Targeted Agent Delays Skeletal Metastases in CRPC

November 23, 2011

Denosumab can delay bone metastases in men with castration-resistant prostate cancer (CRPC), a study found.
 

Cleveland Clinic Urologist To Receive $2 Million Gift for Research

November 18, 2011

J. Stephen Jones, MD, a urologist at Cleveland Clinic's Glickman Urological and Kidney Institute and a member of the Renal & Urology News editorial advisory board, is the recipient of a combined $2 million gift that will support prostate and bladder cancer research.
 
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Dialysis End-stage Renal Disease Hemodialysis Kidney Cancer Overactive Bladder Prostate Cancer PSA Renal Cell Carcinoma Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urology

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions